Literature DB >> 17085643

Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.

Xiyong Liu1, Bingsen Zhou, Lijun Xue, Jennifer Shih, Karen Tye, Wesley Lin, Christina Qi, Peiguo Chu, Frank Un, Wei Wen, Yun Yen.   

Abstract

PURPOSE: Previous gene transfection studies have shown that the accumulation of human ribonucleotide reductase small subunit M2 (hRRM2) enhances cellular transformation, tumorigenesis, and malignancy potential. The latest identified small subunit p53R2 has 80% homology to hRRM2. Here, we investigate the role of p53R2 in cancer invasion and metastasis. EXPERIMENTAL
DESIGN: The immunohistochemistry was conducted on a tissue array including 49 primary and 59 metastatic colon adenocarcinoma samples to determine the relationship between p53R2 expression and metastasis. A Matrigel invasive chamber was used to sort the highly invasive cells and to evaluate the invasion potential of p53R2.
RESULTS: Univariate and multivariate analyses revealed that p53R2 is negatively related to the metastasis of colon adenocarcinoma samples (odds ratio, 0.23; P<0.05). The decrease of p53R2 is associated with cell invasion potential, which was observed in both p53 wild-type (KB) and mutant (PC-3 and Mia PaCa-2) cell lines. An increase in p53R2 expression by gene transfection significantly reduced the cellular invasion potential to 54% and 30% in KB and PC-3 cells, respectively, whereas inhibition of p53R2 by short interfering RNA resulted in a 3-fold increase in cell migration.
CONCLUSIONS: Opposite regulation of hRRM2 and p53R2 in invasion potential might play a critical role in determining the invasion and metastasis phenotype in cancer cells. The expression level of ribonucleotide reductase small subunits may serve as a biomarker to predict the malignancy potential of human cancers in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085643     DOI: 10.1158/1078-0432.CCR-06-0799

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.

Authors:  Chiu-Chun Chang; Chun-Che Lin; Chia-Hung Wang; Chi-Chou Huang; Tao-Wei Ke; Po-Li Wei; Ken-Tu Yeh; Kai-Cheng Hsu; Nan-Yung Hsu; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2018-03-19       Impact factor: 2.967

2.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Authors:  Xiyong Liu; Lily Lai; Xiaochen Wang; Lijun Xue; Sofia Leora; Jun Wu; Shuya Hu; Keqiang Zhang; Mei-Ling Kuo; Lun Zhou; Hang Zhang; Yafan Wang; Yan Wang; Bingsen Zhou; Rebecca A Nelson; Shu Zheng; Suzhan Zhang; Peiguo Chu; Yun Yen
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

3.  E2F1 regulates p53R2 gene expression in p53-deficient cells.

Authors:  Jun-Juan Qi; Ling Liu; Ji-Xiang Cao; Guo-Shun An; Shu-Yan Li; Gang Li; Hong-Ti Jia; Ju-Hua Ni
Journal:  Mol Cell Biochem       Date:  2014-10-14       Impact factor: 3.396

4.  Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Authors:  James J Farrell; Jennifer Moughan; Jonathan L Wong; William F Regine; Paul Schaefer; Al B Benson; John S Macdonald; Xiyong Liu; Yun Yen; Raymond Lai; Zhong Zheng; Gerold Bepler; Chandan Guha; Hany Elsaleh
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

5.  p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.

Authors:  Nan-Yung Hsu; Jeng-Yuan Wu; Xiyong Liu; Yun Yen; Chih-Yi Chen; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

6.  Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.

Authors:  Bingsen Zhou; Leila Su; Yate-Ching Yuan; Frank Un; Norby Wang; Madhukar Patel; Bixin Xi; Shuya Hu; Yun Yen
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

7.  p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.

Authors:  Chao Jiang; Rui Xu; Xiao-Xing Li; Yan-Yan Wang; Wen-Qian Liang; Ju-Deng Zeng; Shan-Shan Zhang; Xiao-Yi Xu; Yang Yang; Mei-Yin Zhang; Hui-Yun Wang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2017-08-25       Impact factor: 4.534

8.  Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Authors:  Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 9.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

10.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.

Authors:  Keqiang Zhang; Shuya Hu; Jun Wu; Linling Chen; Jianming Lu; Xiaochen Wang; Xiyong Liu; Bingsen Zhou; Yun Yen
Journal:  Mol Cancer       Date:  2009-02-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.